Clinical Trials Browser

Has results × trastuzumab deruxtecan × Clear all

Brain Neoplasms, Breast Neoplasms

HER2-mutant Non-Small Cell Lung Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Neoplasm Metastasis

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Neoplasm Metastasis

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Adenocarcinoma, Stomach Neoplasms

Neoplasm Metastasis, Neoplasms

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

Breast Neoplasms, Neoplasms

Adenocarcinoma, Gastrointestinal Neoplasms

Neoplasms, Colorectal Neoplasms

Clinical Trials

DESTINY-B12

DL-05

BEGONIA

TRANSCENDER

HER2CLIMB-04

DPT01

DB-06

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

DESTINY-CRC02

DESTINY-LUNG02

HUDSON

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

DESTINY-Breast01

DEBBRAH

DESTINY-Lung01

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

DG-06

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)